Autor: |
Susan L. Uprichard, Amornrat O’Brien, Monika Evdokimova, Cynthia L. Rowe, Cara Joyce, Matthew Hackbart, Yazmin E. Cruz-Pulido, Courtney A. Cohen, Michelle L. Rock, John M. Dye, Paul Kuehnert, Keersten M. Ricks, Marybeth Casper, Lori Linhart, Katrina Anderson, Laura Kirk, Jack A. Maggiore, Andrew S. Herbert, Nina M. Clark, Gail E. Reid, Susan C. Baker |
Jazyk: |
angličtina |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
Viruses, Vol 14, Iss 2, p 370 (2022) |
Druh dokumentu: |
article |
ISSN: |
1999-4915 |
DOI: |
10.3390/v14020370 |
Popis: |
Understanding the magnitude of responses to vaccination during the ongoing SARS-CoV-2 pandemic is essential for ultimate mitigation of the disease. Here, we describe a cohort of 102 subjects (70 COVID-19-naïve, 32 COVID-19-experienced) who received two doses of one of the mRNA vaccines (BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna)). We document that a single exposure to antigen via infection or vaccination induces a variable antibody response which is affected by age, gender, race, and co-morbidities. In response to a second antigen dose, both COVID-19-naïve and experienced subjects exhibited elevated levels of anti-spike and SARS-CoV-2 neutralizing activity; however, COVID-19-experienced individuals achieved higher antibody levels and neutralization activity as a group. The COVID-19-experienced subjects exhibited no significant increase in antibody or neutralization titer in response to the second vaccine dose (i.e., third antigen exposure). Finally, we found that COVID-19-naïve individuals who received the Moderna vaccine exhibited a more robust boost response to the second vaccine dose (p = 0.004) as compared to the response to Pfizer–BioNTech. Ongoing studies with this cohort will continue to contribute to our understanding of the range and durability of responses to SARS-CoV-2 mRNA vaccines. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|